A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. | Ann Oncol;30(11): 1846, 2019 11 01. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial.

Kulke, M H; Ruszniewski, P; Van Cutsem, E; Lombard-Bohas, C; Valle, J W; De Herder, W W; Pavel, M; Degtyarev, E; Brase, J C; Bubuteishvili-Pacaud, L; Voi, M; Salazar, R; Borbath, I; Fazio, N; Smith, D; Capdevila, J; Riechelmann, R P; Yao, J C.

Ann Oncol ; 30(11): 1846, 2019 11 01.

Article in En | MEDLINE | ID: mdl-31407000

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2019 Document type: Article Country of publication:

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2019 Document type: Article Country of publication: